Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Download Data

Icosavax Inc Financing Cash Flow 2 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023: -52.67%

Icosavax Inc Financing Cash Flow 2 year CAGR is -52.67% for the Trailing 12 Months (TTM) ending September 30, 2023, a 21.54% change year over year. Financing Cash Flow is the net cash flow resulting from a company's financing activities, including repayment/issuance of debt, equity repurchases, dividends paid, and other financial activities. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Icosavax Inc Financing Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 452.00 K, a -99.85% change year over year.
Icosavax Inc Financing Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 306.22 M, a 7,215.38% change year over year.
Icosavax Inc Financing Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 4.19 M.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends